Determination and pharmacokinetic study of AZD‐3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer

BACKGROUND: AZD‐3759 is a new, potent, oral, active central nervous system‐penetrant EGFR inhibitor. Despite promising clinical activity among patients pretreated and never treated with EGFR‐tyrosine kinase inhibitors, no time saving pharmacokinetic study method has been reported in an animal model....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Thorac Cancer
Autores principales: Wu, Qingjun, Hua, Ailian, Sun, Yaoguang, Ma, Chao, Tian, Wenxin, Huang, Chuan, Yu, Hanbo, Jiao, Peng, Wang, Shuanghu, Tong, Hongfeng, Qiu, Weiwen
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6209780/
https://ncbi.nlm.nih.gov/pubmed/30252204
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12843
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares